Related Experiment Video
Updated: Jun 27, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Is there a role for everolimus in the treatment of RA?
1Rheumatic Diseases Division, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8884, USA. nancy.olsen@utsouthwestern.edu
Abstract:
The past decade has seen remarkable advances in the treatment of rheumatoid arthritis. Although this is good news for the majority of patients, one consequence is that the environment for the development of new drugs has become difficult as a result of high expectations for efficacy. Nevertheless, there remains a subgroup of patients with rheumatoid arthritis who are not candidates for treatment with the newer biologic agents and in whom oral DMARDs have certain advantages. A recent report by Bruyn et al. suggests that the proliferation-signal inhibitor everolimus could have unique properties, in addition to a convenient once-daily oral dosing schedule, that might fit this niche in the therapeutic armamentarium. Further studies are required, however, to confirm the disease-modifying effects and adverse event profile of this drug.
Insights
Everolimus, an oral drug, shows promise for rheumatoid arthritis patients unsuitable for biologics. Further research is needed to confirm its disease-modifying effects and safety profile.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Recent advances in rheumatoid arthritis treatment have raised efficacy expectations, complicating new drug development.
- A subset of rheumatoid arthritis patients cannot use newer biologic agents and may benefit from oral disease-modifying antirheumatic drugs (DMARDs).
Discussion:
- Everolimus, a proliferation-signal inhibitor, is being investigated for rheumatoid arthritis.
- Its potential advantages include convenient once-daily oral dosing and unique properties for a specific patient niche.
Key Insights:
- Everolimus may offer a therapeutic option for rheumatoid arthritis patients who are not candidates for biologic therapies.
- The drug's oral administration and potential efficacy warrant further investigation.
Outlook:
- Confirmatory studies are necessary to validate the disease-modifying effects of everolimus in rheumatoid arthritis.
- Comprehensive evaluation of the adverse event profile is crucial before widespread clinical adoption.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Rheumatic Heart Disease III: Medical Management
The JAK-STAT Signaling Pathway
Pericarditis III: Medical Management
Antihypertensive Drugs: Direct Renin Inhibitors
Myocarditis III: Medical Management
